Johnson & Johnson receives market authorization for OTTAVA and new oncology and hematology drugs
On October 13, 2026, Johnson & Johnson announced market authorization of the OTTAVA system – the world’s first robotic device integrated into an operating table – approval of IMAAVY for warm autoimmune hemolytic anemia (wAIHA) and the start of priority review for RYBREVANT FASPRO for advanced head and neck cancer. The moves expand the company’s portfolio in robotic surgery, hematology and oncology.
Key points
- The company announced market authorization for OTTAVA, approval of IMAAVY in wAIHA and priority review of RYBREVANT FASPRO for advanced head and neck cancer.
- The drug IMAAVY is aimed at patients with warm autoimmune hemolytic anemia, and RYBREVANT FASPRO is for people with advanced head and neck tumors.
- The FDA granted market authorization for OTTAVA, approved IMAAVY and gave priority review to RYBREVANT FASPRO.
What happened
The company announced market authorization for OTTAVA, approval of IMAAVY in wAIHA and priority review of RYBREVANT FASPRO for advanced head and neck cancer.
Who it matters to
The drug IMAAVY is aimed at patients with warm autoimmune hemolytic anemia, and RYBREVANT FASPRO is for people with advanced head and neck tumors.
Evidence
The FDA granted market authorization for OTTAVA, approved IMAAVY and gave priority review to RYBREVANT FASPRO.
Next step
The FDA will continue priority review of RYBREVANT FASPRO; a final decision date was not provided.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Johnson & Johnson
A notification in your browser or on your phone when we publish about Johnson & Johnson. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
